Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia

Acute Myeloid Leukaemia (AML) is a rare but serious group of diseases that require critical decision-making for curative treatment. Over the past decade, scientific discovery has revealed dozens of prognostic gene mutations for AML while sequencing costs have plummeted. In this study, we compared th...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Cressman, S, Karsan, A, Hogge, DE, McPherson, E, Bolbocean, C, Regier, DA, Peacock, SJ
Materyal Türü: Journal article
Dil:English
Baskı/Yayın Bilgisi: Wiley 2016

Benzer Materyaller